2602 Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC). The SPAZO study (SOGUG)

Authors :: Laura Basterrechea
B. Pérez-Valderrama
Á. Rodríguez Sánchez
A. Pinto
M.J. Mendez Vidal
Daniel Castellano
R.D. García Marrero
J.A. Arranz Arija
S. Vazquez Estevez
Pablo Gajate
Marta López-Brea
J.A. Meana García
P. Borrega
O. Reig Torras
I. García Carbonero
E.M. Fernandez Parra
P. Jiménez Gallego
C. Suarez Rodriguez
C. Molins Palau
Christian Santander
Source :: European Journal of Cancer. 51:S512
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
First line
medicine.disease
Pazopanib
Renal cell carcinoma
Internal medicine
Prognostic model
medicine
Metastatic renal carcinoma
business
medicine.drug

Tools